Idioma:

Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers

Evans, D G ; Gaarenstroom, K N ; Stirling, D ; Shenton, A ; Maehle, L ; Dørum, A ; Steel, M ; Lalloo, F ; Apold, J ; Porteous, M E ; Vasen, H F A ; van Asperen, C J ; Moller, P

Journal of medical genetics, 2009-09, Vol.46 (9), p.593-597 [Periódico revisado por pares]

London: BMJ Publishing Group Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers
Autor: Evans, D G ; Gaarenstroom, K N ; Stirling, D ; Shenton, A ; Maehle, L ; Dørum, A ; Steel, M ; Lalloo, F ; Apold, J ; Porteous, M E ; Vasen, H F A ; van Asperen, C J ; Moller, P
Assuntos: Biological and medical sciences ; CA-125 Antigen - blood ; Cohort Studies ; DNA Mismatch Repair ; Female ; Female genital diseases ; Fundamental and applied biological sciences. Psychology ; General aspects. Genetic counseling ; Genes, BRCA1 ; Genes, BRCA2 ; Genetic Testing - methods ; Genetics of eukaryotes. Biological and molecular evolution ; Gynecology. Andrology. Obstetrics ; Humans ; Kaplan-Meier Estimate ; Medical genetics ; Medical sciences ; Molecular and cellular biology ; Neoplasm Staging ; Ovarian Neoplasms - blood ; Ovarian Neoplasms - diagnosis ; Ovarian Neoplasms - diagnostic imaging ; Ovarian Neoplasms - genetics ; Prognosis ; Tumors ; Ultrasonography
É parte de: Journal of medical genetics, 2009-09, Vol.46 (9), p.593-597
Notas: local:jmedgenet;46/9/593
href:jmedgenet-46-593.pdf
ark:/67375/NVC-2MLC8341-2
ArticleID:mg58248
PMID:18413372
istex:DDD13C89CCA74C99516F154CE9DAE639CAEA991F
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Aim:To assess the effectiveness of annual ovarian cancer screening (transvaginal ultrasound and serum CA125 estimation) in reducing mortality from ovarian cancer in women at increased genetic risk.Patients and methods:A cohort of 3532 women at increased risk of ovarian cancer was screened at five European centres between January 1991 and March 2007. Survival from diagnosis of ovarian cancer was calculated using Kaplan–Meier analysis and compared for proven BRCA1/2 carriers with non-carriers and whether the cancer was detected at prevalence or post-prevalent scan. Screening was performed by annual transvaginal ultrasound and serum CA125 measurement.Results:64 epithelial ovarian malignancies (59 invasive and 5 borderline), developed in the cohort. 26 tumours were detected at prevalent round; there were 27 incident detected cancers and 11 interval. 65% of cancers were stage 3 or 4, however, stage and survival were little different for prevalent versus post-prevalent cancers. Five year and 10 year survival in 49 BRCA1/2 mutation carriers was 58.6% (95% CI 50.9% to 66.3%) and 36% (95% CI 27% to 45%), which was significantly worse than for 15 non-BRCA carriers (91.8%, 95% CI 84% to 99.6%, both 5 and 10 year survival p = 0.015). However, when borderline tumours were excluded, the difference in survival between carriers and non-carriers was no longer significant.Conclusion:Annual surveillance, by transvaginal ultrasound scanning and serum CA125 measurement, in women at increased familial risk of ovarian cancer is ineffective in detecting tumours at a sufficiently early stage to influence substantially survival in BRCA1/2 carriers.
Editor: London: BMJ Publishing Group Ltd
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers

Evans, D G ; Gaarenstroom, K N ; Stirling, D ; Shenton, A ; Maehle, L ; Dørum, A ; Steel, M ; Lalloo, F ; Apold, J ; Porteous, M E ; Vasen, H F A ; van Asperen, C J ; Moller, P

London: BMJ Publishing Group Ltd

Buscando em bases de dados remotas. Favor aguardar.